Erlizumab Biosimilar - Research Grade

Human

ITGB2ï؟½

5mg/ml

Fab - G1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P05107

Blue ice

CD18 (ITGB2) is the common beta-2 integrin subunit that, paired with alpha chains, governs leukocyte adhesion, migration, and immune-cell function. This research-grade anti-human ITGB2 recombinant Fab fragment is an unconjugated, non-therapeutic analog of erlizumab, intended exclusively for research use only (RUO). Manufactured under rigorous in vivo standards, the ultra-pure, low-endotoxin material is offered in scalable milligram (mg) to gram (g) quantities to support heavy-usage and high-throughput laboratories. It is suited to integrin adhesion-blocking and neutralization assays, in vitro leukocyte function studies, in vivo models of inflammation and ischemia-reperfusion injury, and reference control work in biologics characterization.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.